Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...

Teacher Retirement System of Texas increased its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 18.5% ...

Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and ...

Immunovant said on Wednesday its experimental treatment for a type of chronic muscle weakness improved patients' symptoms and that it aimed to use the data to accelerate the development of a newer ...

The company continues to focus on a next-generation drug while batoclimab’s testing in thyroid eye disease wraps up.

Immunovant (NASDAQ:IMVT) traded lower in the premarket on Wednesday after the company announced clinical trial data related ...

The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.

Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...

Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...

Immunovant (IMVT) reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study ...

Safety and tolerability were observed to be consistent with prior batoclimab studies. Immunovant plans to initiate potentially registrational studies in both MG and CIDP with lead asset IMVT-1402 and ...

March 19 (Reuters) - Immunovant (IMVT.O), opens new tab said on Wednesday its experimental treatment for a type of chronic muscle weakness improved patients' symptoms and that it aimed to use the ...